Dossier is ready, not submitted. License for use of Dossier is related to initial downpayment and commitment to bulk purchase.  

Daunorubicin is classified as an antineoplastic, according ATC index.

Offer is valid subject to confirmation, country by country. Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

• Croatia - Pharmaceuticals and Biotechnology (18/10/2008)
• Leading Drug Delivery Companies and Technologies (14/10/2008)
• Valuing Pharmaceutical Innovation (14/10/2008)

• Cyproterone (10/07/2006)
• Cisplatin (10/07/2006)
• Cetrizine (10/07/2006)
• Carvedilol (10/07/2006)
• Capecitabine (10/07/2006)
• Anastrazole (10/07/2006)
• Finasteride (09/07/2006)
• Doxazosin (09/07/2006)
• Carboplatin (09/07/2006)